International, randomized, placebo-controlled, double-blindphase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1

Journal of Clinical Oncology

Volumn 30, Issue 23, 2012, Pages 2829-2836

  Scagliotti, Giorgio V ^a   Vynnychenko, Ihor ^b   Park, Keunchil ^d   Ichinose, Yukito ^e   Kubota, Kaoru ^f   Blackhall, Fiona ^g   Pirker, Robert ^h   Galiulin, Rinat ⁱ   Ciuleanu, Tudor Eliade ^j   Sydorenko, Oleksandr ^c   Dediu, Mircea ^k   Papai Szekely, Zsolt ^l   Banaclocha, Natividad Martinez ^m   McCoy, Sheryl ⁿ   Yao, Bin ⁿ   Hei, Yong Jiang ⁿ   Galimi, Francesco ⁿ   Spigel, David R ^o  

^a UNIVERSITY OF TURIN   (Italy)

^b SUMY STATE UNIVERSITY   (Ukraine)

^c ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ Omsk Regional Oncology Center   (Russian Federation)

^j THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^k Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^l St George Hospital   (Hungary)

^m Hospital General Universitario   (Spain)

ⁿ AMGEN INC   (United States)

^o SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MOTESANIB; PACLITAXEL; PLACEBO; PLACENTAL GROWTH FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER DISEASE; GALLBLADDER ENLARGEMENT; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HEMOPTYSIS; HUMAN; HYPERTENSION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RESPIRATORY FAILURE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PACLITAXEL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; YOUNG ADULT;

EID: 84865095318     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.4987     Document Type: Article

References (29)

1. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
2. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234, 2009
3. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809, 2010
4. Scagliotti G, Govindan R: Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 15:436-446, 2010
5. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
6. Sandler A, Yi J, Dahlberg S, et al: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/ carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5:1416-1423, 2010
7. Polverino A, Coxon A, Starnes C, et al: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, plateletderived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721, 2006 (Pubitemid 44449188)
8. Sherman SI, Wirth LJ, Droz JP, et al: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42, 2008 (Pubitemid 351931094)
9. Rosen LS, Kurzrock R, Mulay M, et al: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-2376, 2007 (Pubitemid 46999207)
10. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
11. Blumenschein GR Jr, Kabbinavar F, Menon H, et al: A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057-2067, 2011
12. Bass MB, Davis MT, Kivman L, et al: Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small-cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 3037)
13. Autiero M, Waltenberger J, Communi D, et al: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936-943, 2003 (Pubitemid 36889938)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Cox DR, Oakes D: Analysis of Survival Data. Boca Raton, FL, Chapman & Hall/CRC, 1984
16. Patterson SD, Davis MT, Mackey J, et al: Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (Pts) with locally recurrent or advanced metastatic breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 1048)
17. Bass MB, Sherman SI, Schlumberger MJ, et al: Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95:5018-5027, 2010
18. Blumenschein GR Jr, Reckamp K, Stephenson GJ, et al: Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/ paclitaxel and/or panitumumab for the treatment of advanced non-small-cell lung cancer. Clin Cancer Res 16:279-290, 2010
19. Kotasek D, Tebbutt N, Desai J, et al: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: A phase 1b study. BMC Cancer 11: 313, 2011
20. Tebbutt NC, Lipton LR, Price TJ, et al: The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors. J Clin Oncol 29, 2011 (suppl; abstr e13555)
21. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
22. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
23. Gatzemeier U, Eisen T, Santoro A, et al: Sorafenib (S) - gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non- small cell lung cancer (NSCLC): phase III NSCLC research EXperience Utilizing Sorafenib (NEXUS) trial. Ann Oncol 21:viii7, 2010 (suppl; abstr LBA16)
24. Goss GD, Arnold A, Shepherd FA, et al: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55, 2010
25. de Boer RH, Arrieta Ó, Yang CH, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074, 2011
26. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A doubleblind, randomised, phase 3 trial. Lancet Oncol 11:619-626, 2010
27. Herbst RS, Blumenschein GRJ, Kim ES, et al: Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol 28:565s, 2010 (suppl; abstr 7609)
28. Scagliotti GV, De Marinis F, Rinaldi M, et al: The role of histology with common first-line regimens for advanced non-small cell lung cancer: A brief report of the retrospective analysis of a threearm randomized trial. J Thorac Oncol 4:1568-1571, 2009
29. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009